104 related articles for article (PubMed ID: 27058707)
1. Neoadjuvant dose-dense chemotherapy for locally advanced breast cancer: a meta-analysis of published studies.
Petrelli F; Coinu A; Lonati V; Cabiddu M; Ghilardi M; Borgonovo K; Barni S
Anticancer Drugs; 2016 Aug; 27(7):702-8. PubMed ID: 27058707
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials.
Petrelli F; Cabiddu M; Coinu A; Borgonovo K; Ghilardi M; Lonati V; Barni S
Breast Cancer Res Treat; 2015 Jun; 151(2):251-9. PubMed ID: 25917869
[TBL] [Abstract][Full Text] [Related]
3. Dose-dense chemotherapy versus conventional chemotherapy for early breast cancer: a systematic review with meta-analysis.
Lemos Duarte I; da Silveira Nogueira Lima JP; Passos Lima CS; Deeke Sasse A
Breast; 2012 Jun; 21(3):343-9. PubMed ID: 22425607
[TBL] [Abstract][Full Text] [Related]
4. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
Berruti A; Amoroso V; Gallo F; Bertaglia V; Simoncini E; Pedersini R; Ferrari L; Bottini A; Bruzzi P; Sormani MP
J Clin Oncol; 2014 Dec; 32(34):3883-91. PubMed ID: 25349292
[TBL] [Abstract][Full Text] [Related]
5. [Response and prognosis of neoadjuvant dose-dense or standard schedule chemotherapy with anthracyclines and taxanes for Luminal B breast cancer].
Qiu AF; Miao ZL; Ge GK; Wang CB; Bian J; Ma HY; Xu Q
Zhonghua Yi Xue Za Zhi; 2017 Nov; 97(44):3466-3470. PubMed ID: 29275580
[No Abstract] [Full Text] [Related]
6. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer.
Petrelli F; Coinu A; Lonati V; Barni S
Int J Colorectal Dis; 2015 Apr; 30(4):447-57. PubMed ID: 25433820
[TBL] [Abstract][Full Text] [Related]
7. Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials.
Bria E; Carbognin L; Furlanetto J; Pilotto S; Bonomi M; Guarneri V; Vicentini C; Brunelli M; Nortilli R; Pellini F; Sperduti I; Giannarelli D; Pollini GP; Conte P; Tortora G
Cancer Treat Rev; 2014 Aug; 40(7):847-56. PubMed ID: 24877987
[TBL] [Abstract][Full Text] [Related]
8. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies.
Tomasello G; Petrelli F; Ghidini M; Pezzica E; Passalacqua R; Steccanella F; Turati L; Sgroi G; Barni S
Eur J Surg Oncol; 2017 Sep; 43(9):1607-1616. PubMed ID: 28347525
[TBL] [Abstract][Full Text] [Related]
9. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis.
Li Z; Shan F; Wang Y; Zhang Y; Zhang L; Li S; Jia Y; Xue K; Miao R; Li Z; Ji J
PLoS One; 2018; 13(1):e0189294. PubMed ID: 29370182
[TBL] [Abstract][Full Text] [Related]
10. Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.
Kroep JR; Charehbili A; Coleman RE; Aft RL; Hasegawa Y; Winter MC; Weilbaecher K; Akazawa K; Hinsley S; Putter H; Liefers GJ; Nortier JWR; Kohno N
Eur J Cancer; 2016 Feb; 54():57-63. PubMed ID: 26722766
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.
Natori A; Ethier JL; Amir E; Cescon DW
Eur J Cancer; 2017 May; 77():40-47. PubMed ID: 28355581
[TBL] [Abstract][Full Text] [Related]
12. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials.
Cuppone F; Bria E; Carlini P; Milella M; Felici A; Sperduti I; Nisticò C; Terzoli E; Cognetti F; Giannarelli D
Cancer; 2008 Jul; 113(2):238-46. PubMed ID: 18470908
[TBL] [Abstract][Full Text] [Related]
13. Dual Block with Lapatinib and Trastuzumab Versus Single-Agent Trastuzumab Combined with Chemotherapy as Neoadjuvant Treatment of HER2-Positive Breast Cancer: A Meta-analysis of Randomized Trials.
Clavarezza M; Puntoni M; Gennari A; Paleari L; Provinciali N; D'Amico M; DeCensi A
Clin Cancer Res; 2016 Sep; 22(18):4594-603. PubMed ID: 27140927
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
[TBL] [Abstract][Full Text] [Related]
16. Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients.
Ding Y; Ding K; Yang H; He X; Mo W; Ding X
PLoS One; 2020; 15(5):e0234058. PubMed ID: 32470093
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
[TBL] [Abstract][Full Text] [Related]
18. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.
Petrelli F; Coinu A; Cabiddu M; Ghilardi M; Vavassori I; Barni S
Eur Urol; 2014 Feb; 65(2):350-7. PubMed ID: 23849998
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials.
Zhang ZC; Xu QN; Lin SL; Li XY
PLoS One; 2016; 11(10):e0164663. PubMed ID: 27741288
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients.
Qin YY; Li H; Guo XJ; Ye XF; Wei X; Zhou YH; Zhang XJ; Wang C; Qian W; Lu J; He J
PLoS One; 2011; 6(11):e26946. PubMed ID: 22069477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]